Find out about conditions, symptoms and treatments, including what to do and when to get help
Humshaugh & Wark Medical Group
Medicines A to Z
Find out how your medicine works, how and when to take it, and possible side effects
Obesity Injections, Tirzepatide (Mounjaro)
A pathway is being developed in our ICB area (North East and North Cumbria) for the delivery of weight loss injections. We currently do not have a contract for delivering this at Humshaugh & Wark Medical Group. As soon as we are in a position to offer the treatment we will update this notice.
To be eligible for the NHS injection a patient must have a BMI ≥40 and 4 out of the following 5 conditions.:
- Atherosclerotic Cardiovascular Disease – IHD, CVA/TIA, PAD, HF
- Hypertension – On treatment
- High Cholesterol – On Lipid Lowering Therapy (or LDL >=4.1 or HDL <1.0 for men or HDL <1.3 women or fasting triglycerides >=1.7)
- Obstructive Sleep Apnoea (OSA) – Meets criteria for CPAP or equivalent
- Diabetes Type 2
Phased Primary Care Cohorts (2025–2028)
The programme will develop over the coming years as follows:
- Cohort I (2025-26 ): 4 or more of the comorbidities listed above and BMI ≥40
- Cohort II (2026-27): 4 or more comorbidities listed above and BMI 35-39.9
- Cohort III (2026-2028): 3 or more comorbidities listed above and BMI ≥40
Page last reviewed: 11 July 2025
Page created: 17 April 2025
Page created: 17 April 2025